- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04431518
PK of JULUCA in Hemodialysis
The Steady-State Pharmacokinetics of Dolutegravir/Rilpivirine Fixed Dose Combination (FDC) in Patients With End Stage Renal Disease (ESRD) Requiring Hemodialysis
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Samir K Gupta, MD
- Phone Number: 317-274-7926
- Email: sgupta1@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Samir Gupta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Negative HIV antibody testing at screening.
For the ESRD requiring HD study group: ESRD requiring chronic hemodialysis for at least 6 months at an established center (not home dialysis).
NOTE: The approximate date that hemodialysis was initiated should be reported, if known.
For the normal renal function group: Estimated CrCl (using the Cockcroft-Gault equation) at screening ≥75mL/min.
- Availability of alternative venous access (not used for dialysis) for the purpose of PK sampling.
The following laboratory values obtained within 30 days prior to study entry (obtained either at screening or done as part of routine clinical care):
- AST (SGOT) and ALT (SGPT) less than or equal to ULN
- Total bilirubin less than or equal to 1.5 x ULN
- Hemoglobin greater than or equal to 8.0 mg/dL
- A negative serum pregnancy test result at screening for all women of reproductive potential who have not reached menopause or undergone hysterectomy, bilateral oophorectomy, or tubal ligation.
- Males and females, age 18-65 years.
- Ability and willingness of participant or legal guardian/representative to provide written informed consent.
Exclusion Criteria:
- Known allergy or hypersensitivity to either dolutegravir or rilpivirine
- Use of peritoneal dialysis.
- Serious illnesses, other than ESRD, requiring systemic treatment and/or hospitalization within 30 days prior to the Screening Visit.
- Known liver cirrhosis, unstable liver disease (presence of ascites, encephalopathy, coagulopathy, esophageal/gastric varices), Child-Pugh Class A, B, or C, or known biliary abnormalities (except for known Gilbert's syndrome or asymptomatic gallstones).
- Hepatitis B surface antigen or hepatitis C antibody with detectable RNA at screening.
- Known gastrointestinal disease that may lead to poor absorption of the study drugs.
- Known hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
Any of the following gastrointestinal signs or symptoms of Grade ≥ 2 within 7 days prior to the Screening Visit or during study drug administration prior to the Intensive PK Study Visit:
- nausea
- vomiting
- diarrhea
- abdominal pain
Use of any of the following within 30 days of initiating study drug:
- Medications known to appreciably inhibit or induce CYP3A enzymes, P-glycoprotein, or UGT1A1 or UGT1A4 enzymes (e.g., anticonvulsants such as carbamazepine, phenytoin, oxacarbamazepine; antimycobacterials such as rifampin, rifabutin and rifapentine; antifungal agents such as ketoconazole, fluconazole and itraconazole; verapamil, clarithromycin, erythromycin)
- St. John's Wort, echinacea, grapefruits or grapefruit juice, garlic supplements, ginseng, golden seal, and milk thistle
- Cancer chemotherapeutic agents
- Investigational agents
- Immunomodulators, including systemic steroids greater than or equal to 100 mg/day of prednisone (Note: Topical and inhaled corticosteroids are allowed.)
- Dofetilide
- Positive pre-study drug screen. Drugs that will be screened for include amphetamines, barbiturates, cocaine and phencyclidine (PCP). Active injected drug users will be excluded from this study.
- Use of proton pump inhibitors within 7 days of initiating study drug (H2 blockers are permitted).
- Pregnancy and/or breast-feeding.
- Moderate to severe depression, defined as a PHQ-9 ≥ 10 at Screening.
- Significant change (i.e., more than a 50% change) in tobacco smoking habit within 6 weeks prior to the Screening Visit. Participants who have recently stopped smoking should have stopped smoking more than 6 weeks prior to the Screening Visit. Participants who have recently started smoking should have started more than 6 weeks prior to the Screening Visit.
- QTc interval greater than 500 msec at Screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hemodialysis Group
Receipt of JULUCA one pill per day up to 14 days
|
One dose of JULUCA will be taken daily for up to 14 days
|
Active Comparator: Normal Renal Function Group
Receipt of JULUCA one pill per day up to 14 days
|
One dose of JULUCA will be taken daily for up to 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DTG Ctau
Time Frame: 11-14 days
|
Steady-state plasma Ctau for dolutegravir
|
11-14 days
|
RPV Ctau
Time Frame: 11-14 days
|
Steady-state plasma Ctau for rilpivirine
|
11-14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of DTG and RPV
Time Frame: 26-30 days
|
The attributable adverse events associated with use of DTG and RPV will be assessed during the study.
|
26-30 days
|
DTG and RPV AUC
Time Frame: 11-14 days
|
Steady-state plasma AUC for dolutegravir and rilpivirine
|
11-14 days
|
DTG and RPV Cmax
Time Frame: 11-14 days
|
Steady-stage plasma Cmax for dolutegravir and rilpivirine
|
11-14 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Samir K Gupta, MD, Indiana University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- Dolutegravir, rilpivirine drug combination
Other Study ID Numbers
- ViiV Healthcare IIS 1837
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on JULUCA 50Mg-25Mg Tablet
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownDiabetic Peripheral Neuropathy
-
AstraZenecaCompleted
-
Percheron TherapeuticsRecruitingDuchenne Muscular DystrophyTurkey, United Kingdom, Australia, Serbia, Bulgaria
-
LG ChemCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedDiabetic Neuropathy PeripheralChina
-
Ascletis Pharmaceuticals Co., Ltd.Completed
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
TWi Biotechnology, Inc.CompletedType 2 Diabetes MellitusUnited States, Taiwan
-
CephalonH. Lundbeck A/S; The Parkinson Study GroupTerminatedParkinson DiseaseUnited States, Canada, Puerto Rico